Table 2 Changes in ART during follow-up and reasons for each change.
ART combination | Start | Stop | Reasons for the changes | Lowest number of CD4+ T cells/mmc | Highest HIV-RNA load (copies/ml) |
|---|---|---|---|---|---|
Zidovudine, Lamivudine | 11/1996 | 07/1997 | Upgrade | 147 | -- |
Zidovudine, Lamivudine, Saquinavir | 08/1997 | 02/2000 | Poor adherence, virological failure | 50 | 90,387 |
Stavudine, Lamivudine, Efavirenz | 03/2000 | 04/2000 | Skin rash | 95 | 1,164 |
Stavudine, Lamivudine, Nevirapine | 05/2000 | 08/2000 | Patient decision | 65 | 1,245 |
INTERRUPTION | 09/2000 | 01/2002 | -- | 9 | 472,578 |
Stavudine, Lamivudine | 02/2002 | 04/2002 | Upgrade | -- | -- |
Stavudine, Lamivudine, Lopinavir/r* | 05/2002 | 04/2003 | Patient decision, diarrhea | 74 | <50 |
Tenofovir, Lamivudine, Indinavir/r* | 05/2003 | 01/2009 | Patient decision | 245 | <50 |
Didanosine, Lamivudine, Atazanavir | 02/2009 | 04/2009 | Simplification | 516 | <40 |
Lamivudine, Atazanavir | 05/2009 | 09/2009 | Patient decision | 531 | 119 |
INTERRUPTION | 10/2009 | 02/2010 | -- | 291 | 80,558 |
Emtricitabine/Tenofovir, Darunavir/r* | 02/2010 | -- | -- | 333 | 734 |